|Number of Estimates|
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Market Cap: 1.69 Billion
Primary Exchange: NASDAQ
Shares Outstanding: 69.1 Million
Float: 44.9 Million
Sector: Health Technology
Longest drawdown: 217 trading days
From: 2019-04-12 To: 2020-01-28
Prevail Therapeutics Proposes IPO Terms
via: SeekingAlpha at 2019-06-13 07:46:25:000
Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|